The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Evaluating the optimal approach for managing MSI-H upper GI cancers
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, comments on key considerations in treating high microsatellite instability (MSI-H) gastric and esophagogastric junction (GEJ) cancers. Surgery has typically resulted in favorable outcomes over microsatellite stable upper gastrointestinal (GI) cancers, and neoadjuvant immunotherapy has proven to be efficacious in the metastatic setting. The Phase II INFINITY trial (NCT04817826) additionally suggests that chemotherapy or surgery may be omitted in this setting as well. Further biomarker research is also needed to identify patients who may progress on immunotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
